GlobeNewswire: uniQure Inc. Contains the last 10 of 201 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:56:51ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/28/2836825/0/en/uniQure-Announces-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html?f=22&fvtc=4&fvtv=34429uniQure Announces 2023 Financial Results and Highlights Recent Company Progress2024-02-28T12:05:00Z<![CDATA[~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions and clarity on potential strategies for clinical development expected in 2024 ~]]>https://www.globenewswire.com/news-release/2023/12/19/2798425/0/en/uniQure-Announces-Update-on-Phase-I-II-Clinical-Trials-of-AMT-130-Gene-Therapy-for-the-Treatment-of-Huntington-s-Disease.html?f=22&fvtc=4&fvtv=34429uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease2023-12-19T12:05:00Z<![CDATA[~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~]]>https://www.globenewswire.com/news-release/2023/12/08/2793129/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=34429uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-12-08T12:05:00Z<![CDATA[LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees.]]>https://www.globenewswire.com/news-release/2023/11/29/2787620/0/en/uniQure-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AMT-191-Gene-Therapy-for-Fabry-Disease.html?f=22&fvtc=4&fvtv=34429uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease2023-11-29T12:05:00Z<![CDATA[Patient enrollment expected to begin in first half of 2024 Patient enrollment expected to begin in first half of 2024]]>https://www.globenewswire.com/news-release/2023/11/07/2774943/0/en/uniQure-Announces-Third-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html?f=22&fvtc=4&fvtv=34429uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress2023-11-07T12:05:00Z<![CDATA[~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epilepsy ~]]>https://www.globenewswire.com/news-release/2023/10/24/2765472/0/en/uniQure-Announces-Major-Presence-at-the-European-Society-of-Gene-and-Cell-Therapy-ESGCT-Annual-Meeting.html?f=22&fvtc=4&fvtv=34429uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting2023-10-24T11:05:00Z<![CDATA[LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting being held October 24-27 in Brussels, Belgium.]]>https://www.globenewswire.com/news-release/2023/10/05/2755260/0/en/uniQure-Announces-Strategic-Reorganization-to-Reduce-Operating-Expenses-and-Support-Advancement-of-Multiple-Clinical-Stage-Programs.html?f=22&fvtc=4&fvtv=34429uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs2023-10-05T11:05:00Z<![CDATA[~ Reduction of 28% of workforce not related to HEMGENIX® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~]]>https://www.globenewswire.com/news-release/2023/10/02/2752634/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=34429uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-10-02T11:05:00Z<![CDATA[LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees.]]>https://www.globenewswire.com/news-release/2023/09/05/2737179/0/en/uniQure-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AMT-260-Gene-Therapy-for-Refractory-Mesial-Temporal-Lobe-Epilepsy.html?f=22&fvtc=4&fvtv=34429uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy2023-09-05T11:05:00Z<![CDATA[Clinical trial initiation expected in the fourth quarter of 2023 Clinical trial initiation expected in the fourth quarter of 2023]]>https://www.globenewswire.com/news-release/2023/08/01/2715661/0/en/uniQure-Announces-Second-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html?f=22&fvtc=4&fvtv=34429uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress2023-08-01T11:05:00Z<![CDATA[~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington’s disease showing preservation of function compared to baseline and clinical benefits relative to natural history; both dose cohorts of AMT-130 continue to be generally well-tolerated ~]]>